VivoSeq
Other

Morbidity

0

Pipeline Programs

3

Active Trials

0

Companies Involved

Morbidity is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

7/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

14

clinical trials

Completed10 · 71%
Recruiting2 · 14%
Terminated1 · 7%
Active, not recruiting1 · 7%

Trial Activity

14 trials

MDMA for AUD/PTSD Comorbidity
Recruiting··Phase 2·NCT05943665·18 enrolled
Valproate Efficacy in Cocaine-Bipolar Comorbidity
Completed·UUniversity of Miami·Phase 1/2·NCT00240110·152 enrolled
Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery
Terminated··N/A·NCT00328094·242 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)